Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
royalties
Pharma
In royalty dispute, UK appeals court sides with GSK over AZ
GSK was previously ordered to pay AstraZeneca a larger share of total sales on its PARP inhibitor Zejula. But now the decision is reversed.
Zoey Becker
Feb 14, 2024 8:22am
Royalty Pharma strikes $150M Skytrofa royalty deal with Ascendis
Sep 6, 2023 11:28am
Arbitration win over J&J gives Alkermes a $425M boost
Jun 6, 2023 3:23pm
After Hemgenix approvals, uniQure inks $400M sale of royalties
May 15, 2023 3:10pm
AZ wins royalties case against GSK over PARP inhibitor Zejula
Apr 5, 2023 7:11pm
Roche takes Biogen to court over royalties for Tysabri
Mar 1, 2023 5:10pm
